logo
  Join        Login             Stock Quote

Idenix Pharmaceuticals (IDIX) Initiated As 'Buy' By Deutsche Bank; PT $7

 November 28, 2012 01:49 PM
 


(By Balachander) Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) shares were initiated with a "Buy" rating and price target of $7 by Deutsche Bank (DB).

"We think current levels reflect a worst case (only royalties & no pipeline)," the bank wrote. "We see an upside case for a re-emerging HCV platform in early '13."

DB thinks IDIX is high risk due to lack of visibility, but also high reward over next 12 months.

The bank believes that IDX-184 has a good shot at getting off partial hold in early 2013 but with increased risk mgmt on guanosine program.

DB wrote that current shares reflect no value for pipeline. FDA nuke hold decision in early '13 is KEY & could get IDX-184 &IDX-368 back in clinic.

[Related -Stocks End Mixed Amid Fed Concerns; Idenix Pharmaceuticals Inc (IDIX) Tumbles]

The bank is of the view that announcement of a clinical collabo with another drug class represents ANOTHER upside catalyst in 1H13. DB said that investors may assign value upon collabo since it suggests increased likelihood of IDX-719 drug sales.

Cambridge, Massachusetts-based Idenix is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases.

The stock, which has been trading in the 52-week range of $3.35 to $15.25, soared 14.38 percent to trade at $5.17 on Wednesday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSolar and Biotechnology Stocks Rally as Rational Exuberance Dominates

Solar stocks are rallying due to positive earnings and deals. Biotechnology stocks are also rallying due to read on...

article imageA Hefty Upside Surprise For February Payrolls

Private payrolls increased substantially more than expected in February, delivering an encouraging dose of read on...

article imageWarren Buffett’s Stellar Record In Defying Economic Gravity

One of the more intriguing observations in Berkshire Hathaway’s new letter to shareholders is Warren read on...

article imageDebate Around the 2015 Rate Hike Intensifies

Following Janet Yellen's Senate Banking Committee testimony, the Fed seems to be quite deliberate in read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.